Findings

What do systematic reviews say?

213 questions · 219 findings · 19 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 25 · 11.4%GRADE not reported 33 · 15.1%Very low 70 · 32%Low 64 · 29.2%Moderate 18 · 8.2%High 9 · 4.1%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Benzodiazepines vs placebo · Tranquillisation or asleep: sedation ‐ medium termNumber of participants sedated
  Benzodiazepines for psychosis‐induced aggression or agitation 2017 · Cochrane Headline outcomes only
  RR 1.67 [0.42, 6.61]
  1 study · 102 participants
  Very low
Direct match · question page
- Benzodiazepines vs placebo · Response
  Benzodiazepines versus placebo for panic disorder in adults 2019 · Cochrane Headline outcomes only
  RR 1.65 [1.39, 1.96]
  16 studies · 2476 participants
  Low
Direct match · question page
- Benzodiazepines vs placebo · Tardive dyskinesia: no clinically important improvement
  Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
  RR 1.12 [0.6, 2.09]
  2 studies · 32 participants
  Very low
Direct match · question page
- Benzodiazepines vs placebo · Panic symptoms ‐ endpoint score
  Benzodiazepines versus placebo for panic disorder in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 1489 participants
  Very low
Direct match · question page
- Benzodiazepines vs placebo · Remission
  Benzodiazepines versus placebo for panic disorder in adults 2019 · Cochrane Headline outcomes only
  RR 1.61 [1.38, 1.88]
  15 studies · 2907 participants
  Low

Benzodiazepines vs placebo

Response · adults with panic disorder

Benzodiazepines may leads to higher response compared with placebo (low certainty).

1 finding from 1 review

Benzodiazepines versus placebo for panic disorder in adults 2019 · Cochrane Headline outcomes only
RR 1.65 [1.39, 1.96]
16 studies · 2476 participants
Low

Benzodiazepines vs placebo

Leaving the study early · adults with panic disorder

Benzodiazepines may leads to lower total number of dropouts compared with placebo (low certainty).

1 finding from 1 review

Benzodiazepines versus placebo for panic disorder in adults 2019 · Cochrane Headline outcomes only
RR 0.5 [0.39, 0.64]
21 studies · 3558 participants
Low

Benzodiazepines vs placebo

Remission · adults with panic disorder

Benzodiazepines may leads to higher remission compared with placebo (low certainty).

1 finding from 1 review

Benzodiazepines versus placebo for panic disorder in adults 2019 · Cochrane Headline outcomes only
RR 1.61 [1.38, 1.88]
15 studies · 2907 participants
Low

Benzodiazepines vs placebo

panic symptoms · adults with panic disorder

2 findings from 1 review

Benzodiazepines versus placebo for panic disorder in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1489 participants
Very low
Benzodiazepines versus placebo for panic disorder in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 719 participants
Very low

Benzodiazepines vs placebo

Withdrawals due to adverse events · adults with panic disorder

Benzodiazepines may leads to higher number of dropouts due to adverse effects compared with placebo (low certainty).

1 finding from 1 review

Benzodiazepines versus placebo for panic disorder in adults 2019 · Cochrane Headline outcomes only
RR 1.58 [1.16, 2.15]
14 studies · 3263 participants
Low

Benzodiazepines vs placebo

Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether benzodiazepines changes tardive dyskinesia: no clinically important improvement compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
RR 1.12 [0.6, 2.09]
2 studies · 32 participants
Very low

Benzodiazepines vs phenobarbital (as active placebo)

Adverse effect: extrapyramidal symptoms ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzodiazepines vs phenobarbital (as active placebo)

Acceptability · patients with antipsychotic‐induced tardive dyskinesia

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Benzodiazepines vs phenobarbital (as active placebo)

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not measured · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzodiazepines vs placebo

Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether benzodiazepines changes tardive dyskinesia: deterioration in symptoms compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
RR 1.48 [0.22, 9.82]
2 studies · 30 participants
Very low

Benzodiazepines vs placebo

Adverse effect: any adverse event · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzodiazepines vs placebo

Adverse effect: no clinically significant extrapyramidal adverse effects · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzodiazepines vs placebo

Acceptability · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether benzodiazepines changes acceptability of the treatment (measured by participants leaving the… compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
RR 2.73 [0.15, 48.04]
3 studies · 56 participants
Very low

Benzodiazepines vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzodiazepines vs phenobarbital (as active placebo)

Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether benzodiazepines changes tardive dyskinesia: no clinically important improvement compared with phenobarbital (as active placebo) (very low certainty).

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
RR 0.44 [0.2, 0.96]
1 study · 21 participants
Very low

Benzodiazepines vs phenobarbital (as active placebo)

Tardive dyskinesia: deterioration in symptoms ‐ not measured · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzodiazepines vs phenobarbital (as active placebo)

Adverse events: any · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether benzodiazepines changes adverse events: any compared with phenobarbital (as active placebo) (very low certainty).

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
RR 1.53 [0.97, 2.41]
1 study · 21 participants
Very low

Benzodiazepines vs placebo

Tranquillisation or asleep: sedation ‐ medium termNumber of participants sedated · psychosis‐induced aggression or agitation

It is very uncertain whether benzodiazepines changes tranquillisation or asleep: sedation ‐ medium termNumber of… compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines for psychosis‐induced aggression or agitation 2017 · Cochrane Headline outcomes only
RR 1.67 [0.42, 6.61]
1 study · 102 participants
Very low

Benzodiazepines vs antipsychotics

Global impression ‐ need for additional medication ‐ medium term Number of participants requiring additional medication · psychosis‐induced aggression or agitation

1 finding from 1 review

Benzodiazepines for psychosis‐induced aggression or agitation 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 216 participants
Very low

Benzodiazepines vs antipsychotics

Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · psychosis‐induced aggression or agitation

Benzodiazepines may leads to lower adverse effects/events: extrapyramidal symptoms ‐ vs haloperidol ‐… compared with antipsychotics (low certainty).

1 finding from 1 review

Benzodiazepines for psychosis‐induced aggression or agitation 2017 · Cochrane Headline outcomes only
RR 0.13 [0.04, 0.41]
6 studies · 233 participants
Low